Welcome to our dedicated page for Verrica Pharmaceuticals SEC filings (Ticker: VRCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Verrica Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Verrica Pharmaceuticals's regulatory disclosures and financial reporting.
Verrica Pharmaceuticals Inc. (VRCA) reported that its Chief Operating Officer, David Zawitz, purchased 6,000 shares of common stock in an open-market or private transaction on 2026-08-17 at a weighted average price of $4.98 per share. Following this transaction, he directly holds 27,000 shares of Verrica common stock. The shares were bought in multiple trades at prices ranging from $4.90 to $5.00 per share.
Verrica Pharmaceuticals Inc. (VRCA) reported that CEO and President Jayson Rieger purchased common stock in the open market. On August 17, 2026, he bought 5,000 shares at $4.91 per share. On August 14, 2026, he bought 20,000 shares at a weighted average price of $5.06 per share, in multiple trades ranging from $5.04 to $5.088. He also reports 15 shares held indirectly by a child and additional shares held in separate family trusts, for which he disclaims beneficial ownership.
Verrica Pharmaceuticals Inc. (VRCA) reported that its Chief Medical Officer, Noah L. Rosenberg, purchased common stock in two open-market or private transactions. On 2026-08-17, he bought 4,200 shares at a weighted average price of about $4.91 per share, and on 2026-08-18 he bought 2,030 shares at a weighted average price of about $4.92 per share. The prices for each trade reflect weighted averages of multiple executions between $4.90 and $4.95 per share.
Verrica Pharmaceuticals Inc. (VRCA) reported that Interim CFO John J. Kirby purchased common stock in the open market. On 2026-08-18, he bought 5,000 shares at a weighted average price of $4.93 per share, in multiple trades priced between $4.85 and $4.99. After this transaction, he directly owns 23,962 shares of Verrica common stock.
Verrica Pharmaceuticals, a dermatology-focused therapeutics company, reported Q2 2026 revenue of $5.9 million, down from $12.7 million a year earlier as prior results included an $8.0 million Torii milestone; core YCANTH product revenue increased to $5.1 million from $4.5 million. Higher R&D spending on the common warts Phase 3 program and VP‑315, along with expanded commercial infrastructure, drove operating expenses to $19.0 million and a net loss of $13.2 million for the quarter, with a six‑month net loss of $22.8 million.
Cash was $11.2 million at June 30, 2026, with $18.4 million used in operating activities in the first half, leading management to conclude that substantial doubt exists about the company’s ability to continue as a going concern within one year of issuance. A new senior secured PD Credit Agreement provides up to $27.5 million of borrowing capacity, including $12.5 million available at closing, but additional equity, debt or partnership funding is still contemplated. Verrica also recorded a $4.0 million class-action settlement liability and a $2.3 million insurance recovery, resulting in $1.7 million of net legal settlement expense.
Verrica Pharmaceuticals reported second quarter 2026 results highlighted by strong uptake of YCANTH, its FDA-approved treatment for molluscum contagiosum. Dispensed applicator units reached 19,626, up 28.3% sequentially and 46.1% year-over-year. Q2 2026 total revenue was $5.9 million, including U.S. YCANTH net product revenue of $5.1 million, up 18.7% over the previous quarter and 12.3% year-over-year.
Despite product growth, the company recorded a Q2 2026 net loss of $(13,153) thousand, or $(0.62) per share, compared with net income of $204 thousand in Q2 2025. Higher operating expenses, including $10,349 thousand in selling, general and administrative costs, $6,034 thousand in research and development, and a $1,698 thousand legal settlement, contributed to the loss. For the first six months of 2026, net loss was $(22,835) thousand.
Cash was 11,198 (in thousands) at June 30, 2026, with total assets of 36,017 (in thousands) and stockholders’ equity of 4,307 (in thousands). Verrica entered a new credit facility for up to $27.5 million with an entity controlled by its chairman and largest shareholder and states that, based on its current operating plan and assuming full availability of this facility, its cash runway could extend into 2028. The company is advancing a global Phase 3 program to expand YCANTH’s label to common warts, with topline data currently expected in mid-2027, and continues Phase 3 readiness work for VP-315 for non-melanoma skin cancers.
Verrica Pharmaceuticals Inc. director Lawrence Eichenfield received a grant of stock options covering 16,000 shares of common stock. The options have an exercise price of $6.04 per share and expire on June 4, 2036.
These options vest in 12 equal monthly installments beginning on July 5, 2026 and are expected to be fully vested by the next annual meeting of stockholders, assuming he continues to serve as a director through each vesting date. Following this award, he holds 16,000 derivative securities directly.
Verrica Pharmaceuticals Inc. director Diem Nguyen received a grant of stock options covering 16,000 shares of common stock. The options have an exercise price of $6.04 per share and expire on June 4, 2036.
These options were granted as compensation and vest in 12 equal monthly installments beginning on July 5, 2026. They will in any event be fully vested on the date of the next annual meeting of stockholders, subject to Nguyen’s continued service as a director through each vesting date.
Verrica Pharmaceuticals Inc. director Mark A. Prygocki Sr. received a grant of stock options covering 16,000 shares of common stock. The options have an exercise price of $6.0400 per share and represent equity-based compensation rather than an open-market purchase.
These options vest in 12 equal monthly installments beginning on July 5, 2026 and will in any event be fully vested by the date of the next annual meeting of stockholders, subject to his continued service as a director through each vesting date. Following this grant, he holds 16,000 derivative securities directly.
Verrica Pharmaceuticals Inc. CMO Noah L. Rosenberg received a grant of employee stock options for 233,840 shares of Common Stock. The options carry an exercise price of $8.21 per share and expire on December 23, 2035.
The grant was approved by a board committee on December 23, 2025, subject to shareholder approval of an amendment to Verrica's 2018 Equity Incentive Plan, which shareholders later approved on June 5, 2026. All 233,840 options are held directly and are compensation-related.
Vesting is performance-based: 50% of the options vest when the closing sales price on The Nasdaq Capital Market reaches at least $15.00 per share, and the remaining 50% vest when the price reaches at least $25.00 per share, subject to Rosenberg's continuous service through each vesting date.